US Patterns in Clinical Islet Autoantibody Ordering and Results Show Key Differences After Teplizumab Regulatory Approval
Clicks: 1
ID: 313420
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #331 of 362 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Context Recent advances in disease-modifying therapies have increased emphasis on islet autoantibody screening to detect type 1 diabetes prior to clinical onset. Objective Test impacts of teplizumab approval on real-world US autoantibody ordering patterns. Methods Testing for biochemical and islet cytoplasmic autoantibodies in 28,206 nondiabetic individuals (HbA1c<6.5%) before (“PRE”, November 2017-November 2018) versus after (“POST”, November 2022-November 2023) teplizumab approval was analyzed. Results were stratified by age (<20 vs ≥20 years) and glycemia (normoglycemic versus dysglycemic). Results Islet autoantibody testing increased 1.9-fold from the PRE to POST period (p<0.0001 versus other testing), especially in adults and dysglycemic children. Overall testing was more common in adults, and tested adults were more commonly dysglycemic than children. In the POST period, providers were more likely to order 3/4 or 4/4 available biochemical antibodies. For both periods most orders in normoglycemic individuals came from primary care providers, while endocrinologists ordered most testing in dysglycemic groups. Provider-level testing was typically low volume in both periods, with providers ordering 1-3 tests/year accounting for >80% of orders. Among dysglycemic children, multiple antibody positivity in the POST period was 35.6% higher than expected compared to the PRE period (p=0.0003). Conclusion Islet autoantibody testing in nondiabetic individuals increased following teplizumab approval, primarily among adults and dysglycemic children, suggesting that these groups allow for the easiest implementation of screening through clinical care. Despite shifts toward guideline-concordant testing, screening of normoglycemic children by primary care providers remains limited, highlighting the need to further integrate this testing into clinical care pathways.
| Reference Key |
openalex_W7161254286
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sanjay B Dixit, Marco Marcelli, Carmen Tong, Zhen Chen, Lance A. Bare, Emily K Sims |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag200
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.